Abiopharma

Sharps Technology Reports Strong Growth in Q3 2025 as it Advances Execution of Treasury Strategy

BD Onclarity™ HPV Assay for BD COR™ and BD Viper™ LT Systems Receive WHO Prequalification

Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC

LFTD Partners Inc. Reports Q3 2025 Basic EPS of $0.04

4DMT Appoints Kristian Humer as Chief Financial Officer

Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Organon & Co. - Henlius and Organon Announce US FDA Approval ofPOHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

So-Young Reports Unaudited Third Quarter 2025 Financial Results

Autonomix Medical, Inc. Reports Positive Subgroup Results Demonstrating Sustained Improvements in Quality of Life from Post Hoc Analysis of Pancreatic Cancer PoC Study

Inventiva annonce l’exercice intégral de l’Option des Banques portant le montant de lOffre à environ 172,5 millions de dollars